Dr Kuno van der Post
OmniComm Systems, Inc.
Former Medidata® and Oracle® Executive Chosen to Oversee Software Development
Fort Lauderdale, FL, January 05, 2011 - OmniComm Systems, Inc., one of the fastest growing companies in the EDC and eClinical marketplace, today announced the appointment of Keith Howells as Vice President of Engineering. Mr. Howells will be responsible for the ongoing development of the TrialMaster®, eClinical, and TrialOne® product lines at OmniComm.
"I can’t think of a better person to head up our new product development," said Stephen Johnson, President and Chief Operating Officer, OmniComm. "Keith has over 20 years of development experience in the clinical trial industry and will be instrumental in taking our product lines to the next level. His extensive experience in developing integrated solutions is a perfect match for our company’s ongoing strategy. Having worked with Keith at Oracle for seven years, I’ve seen first-hand what he is capable of achieving, and have no doubt that he will draw wisdom from his past experience and continue his success with OmniComm."
Mr. Howells has a proven track record for developing complex, integrated, clinical applications. Most recently, as Senior Vice President of Development for Medidata Solutions, he helped establish a strong market position for their electronic data capture (EDC) technology. Prior to that, Mr. Howells served as Vice President for the Oracle Pharmaceutical Applications group and led the development of one of the first and most successful clinical application suites in clinical research. Under his guidance, both Medidata and Oracle have been able to achieve top market positions.
"OmniComm has an attractive and under-appreciated product line with wide and deep functionality," said Keith Howells. "I am excited about this new opportunity, and look forward to helping the company become a major player in providing leading-edge solutions for clinical research."
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's pricing model is easily understood and allows companies ranging from small, to large, to maximize their clinical research investments. OmniComm Systems, Inc has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey and the United Kingdom, as well as sales offices throughout the U.S. and Europe.
Safe Harbor Disclaimer
Safe Harbor Disclaimer Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.